Skip to content

Effectiveness of Integrative Medical Treatment in Sudden Hearing Loss

Effectiveness of Integrative Medical Treatment in Sudden Hearing Loss

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07235488
Enrollment
64
Registered
2025-11-19
Start date
2024-07-08
Completion date
2026-06-20
Last updated
2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sudden Hearing Loss

Keywords

sudden hearing loss, acupuncture

Brief summary

Sudden hearing loss is an emergency in otolaryngology that requires diagnosis and treatment as soon as possible. The golden treatment period is two weeks since the onset of the disease. However, modern medicine is still unable to fully understand the causes of the disease and in lack of corresponding effective treatments. Current therapies also have their own limitations and side effects. To find an effective and safe treatment, integrating with modern medicine and providing inpatient and outpatient medical care, is an important issue in clinical care. Traditional Chinese medicine has been clinically utilized for a long time with accumulated empirical experience and evidence for its efficacy. It can be used as an alternative therapeutic option for sudden hearing loss. Being with a long period of clinical experience and evidence-based curative effect, acupuncture could be applied as an adjunctive treatment for the sudden hearing loss. Currently, this patient-centered, pragmatic clinical trial compares the effectiveness of using west medicine、combination of west medicine and traditional Chinese medicine. The aim of this study is to explore acceptable and beneficial strategy to reduce the clinical symptoms, to improve quality of life, and decrease medical expenses.

Detailed description

Patients newly diagnosed with sudden deafness were randomly assigned in a 1:1 ratio to two groups: a Western medicine group and an integrated Chinese and Western medicine treatment group. Each group included 32 patients, for a total of 64 patients. Treatment lasted four weeks, starting from the date of admission, and included both inpatient and outpatient care. Western Medicine Treatment: During hospitalization, intravenous steroids were administered. After discharge, oral steroids were administered. For patients who did not respond well to treatment, intratympanic steroid injections were performed. Traditional Chinese Medicine Treatment: Acupuncture was performed once daily for 30 minutes at acupoints around the ear and upper limb on the same side as the affected ear. Six treatment sessions were performed in the first and second weeks, and two sessions were performed in the third and fourth weeks. Primary Outcome: Pure-tone audiograms were performed at baseline, week 1, week 2, and week 4. Secondary Outcome: Tinnitus Handicap Inventory and Dizziness Handicap Inventory were performed at baseline, week 1, week 2, and week 4. Blood biochemistry tests were performed at baseline. Adverse events were recorded throughout the trial.

Interventions

DEVICEAcupuncture

Treatment lasted four weeks, starting from the date of admission, and included both inpatient and outpatient care. Western Medicine Treatment : During hospitalization, intravenous steroids were administered. After discharge, oral steroids were administered. For patients who did not respond well to treatment, intratympanic steroid injections were performed. Traditional Chinese Medicine Treatment : Acupuncture was performed on peri-auricular and ipsilateral upper limb points, including Ermen (TE21), Tinggong (SI19), Tinghui (GB2), Shuaigu (GB8), Yifeng (TE17), Waiguan (TE5), and Zhongzhu (TE3). The treatment was administered once daily for 30 minutes. During the first and second weeks, a total of six sessions were carried out, followed by two sessions per week in the third and fourth weeks.

Treatment lasted four weeks, starting from the date of admission, and included both inpatient and outpatient care. Western Medicine Treatment : During hospitalization, intravenous steroids were administered. After discharge, oral steroids were administered. For patients who did not respond well to treatment, intratympanic steroid injections were performed.

Sponsors

China Medical University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years, both male and female. * Meeting the diagnostic criteria for sudden sensorineural hearing loss (SSNHL), defined as hearing loss of \>30 dB affecting at least three consecutive frequencies within 3 days. * Newly onset of hearing loss within 2 week. * Fully understanding the purpose and procedures of the study and providing signed informed consent.

Exclusion criteria

* Central nervous system lesions such as vestibular schwannoma or traumatic brain injury. * Middle ear or retrocochlear pathology. * History of otologic surgery. * Hemorrhagic disorders or coagulation abnormalities. * Inability to cooperate with examinations due to dementia or psychiatric illness. * Previous treatment for SSNHL on the same affected side within the past 6 months.

Design outcomes

Primary

MeasureTime frameDescription
Pure-tone audiogramsbaseline, week 1, week 2, and week 4Changes from baseline to week 1, week 2, and week 4 of the intervention

Secondary

MeasureTime frameDescription
Tinnitus Handicap Inventorybaseline, week 1, week 2, and week 4Changes from baseline to week 1, week 2, and week 4 of intervention
Dizziness Handicap Inventorybaseline, week 1, week 2, and week 4Changes from baseline to week 1, week 2, and week 4 of intervention
Blood examinationbaselineneutrophil-to-lymphocyte ratio (NLR)
Laboratory examinationbaselineinflammatory cytokine test (IL-1β, IL-6, TNF-α)
Adverse eventsbaseline, week 1, week 2, and week 4Adverse events related to steroid or acupuncture therapy were recorded throughout the trial.

Countries

Taiwan

Contacts

Primary ContactMing-Cheng Huang, M.D., Ph.D.
mchuang1128@gmail.com+886-4-22052121 Ext. 14561

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026